目的

探讨原发性乳腺癌谷胱甘肽-s-转移酶-π(GST-π)、P-糖蛋白(P-gp)和拓扑异构酶-Ⅱ(TOPO-Ⅱ)的表达及其与化疗的关系。

方法

通过免疫组织化学方法检测了84 例原发性乳腺癌中56 例术前未经任何抗肿瘤治疗组和28 例术前辅助化疗组的肿瘤组织中GST-π、P-gp 和TOPO-Ⅱ的表达情况。 同时比较了28 例术前辅助化疗组化疗前后乳腺癌组织中三者的表达阳性率。 成组设计和配对设计的计数资料采用χ² 检验。

结果

乳腺癌组织中GST-π、P-gp 和TOPO-Ⅱ表达与各病理因素无关(P＞0.050);28 例术前化疗组化疗前组织中的GST-π、P-gp 和TOPO-Ⅱ的阳性表达率与56 例未化疗组标本的阳性率差异无统计学意义(χ² 值和P 值分别为0.45,0.504;0.41,0.532;1.20,0.273),但与化疗后组织中蛋白表达阳性率的差异有统计意义(χ² 值和P 值分别为4.57,0.033;3.90,0.048;4.98,0.026),GST-π 和P-gp 的表达较化疗前明显增多,但TOPO-Ⅱ的表达呈下降趋势。

结论

化疗影响了原发性乳腺癌组织中GST-π、P-gp、TOPO-Ⅱ的蛋白表达。 监测其表达对乳腺癌化疗有一定的指导意义。

Objective

To explore the expressions of GST-π,P-gp and TOPO-Ⅱand their correlation with chemotherapy in primary breast cancer.

Methods

By using immunohistochemical S-P method, the expressions of GST-π,P-gp, and TOPO-Ⅱwere retrospectively compared and detected in 84 primary breast cancer cases:( the untreated group of 56 cases and the preoperative adjunctive chemotherapy group of 28 cases). The expressions of adjunctive pre- and post-chemotherapy of breast cancer in the 28 cases were also investigated. Results were analyzed using Chi square test for the numeration data of group design and paired design.

Results

The expressions of GSTπ, P-gp and TOPO-Ⅱin breast cancer tissues were not associated with pathological factors (P＞0.050). The positive expression rates of GST-π,P-gp and TOPO-Ⅱhad no statistical significance between the 28 cases with pre-chemotherapy and the 56 cases of untreated primary breast cancer, with the Chi-square value and P value of 0.45 and 0.504, 0. 41 and 0. 532, and 1. 20 and 0. 273, respectively; but had significant difference between prechemothrapy and postchemotherapy in the 28 cases, with the Chi-square value and p value of 4.57 and 0.033, 3.90 and 0.048, and 4.98 and 0.026, respectively; the positive expression rates of GST-π and P-gp of postchemotherapy increased significantly compared with pretchemotherapy, but the positive expression rate of TOPO-Ⅱshowed a decrease trend after chemotherapy.

Conclusion

Chemotherapy can affect the expressions of GST-π, P-gp and TOPO-Ⅱin primary breast cancer;monitoring their expressions in breast cancer has an important guiding significance.